Accurate IMRT fluence verification for prostate cancer patients using 'in-vivo' measured EPID images and in-room acquired kilovoltage cone-beam CT scans by Ali, A.S.A.M. (Ali) et al.
Ali et al. Radiation Oncology 2013, 8:211
http://www.ro-journal.com/content/8/1/211RESEARCH Open AccessAccurate IMRT fluence verification for prostate
cancer patients using ‘in-vivo’ measured EPID
images and in-room acquired kilovoltage
cone-beam CT scans
Ali SAM Ali*, Maarten LP Dirkx, Ruud M Cools and Ben JM HeijmenAbstract
Background: To investigate for prostate cancer patients the comparison of ‘in-vivo’ measured portal dose images
(PDIs) with predictions based on a kilovoltage cone-beam CT scan (CBCT), acquired during the same treatment
fraction, as an alternative for pre-treatment verification. For evaluation purposes, predictions were also performed
using the patients’ planning CTs (pCT).
Methods: To get reliable CBCT electron densities for PDI predictions, Hounsfield units from the pCT were mapped
onto the CBCT, while accounting for non-rigidity in patient anatomy in an approximate way. PDI prediction
accuracy was first validated for an anatomical phantom, using IMRT treatment plans of ten prostate cancer patients.
Clinical performance was studied using data acquired for 50 prostate cancer patients. For each patient, 4–5 CBCTs
were available, resulting in a total of 1413 evaluated images. Measured and predicted PDIs were compared using
γ-analyses with 3% global dose difference and 3 mm distance to agreement as reference criteria. Moreover,
the pass rate for automated PDI comparison was assessed. To quantify improvements in IMRT fluence verification
accuracy results from multiple fractions were combined by generating a γ-image with values halfway the minimum
and median γ values, pixel by pixel.
Results: For patients, CBCT-based PDI predictions showed a high agreement with measurements, with an average
percentage of rejected pixels of 1.41% only. In spite of possible intra-fraction motion and anatomy changes, this
was only slightly larger than for phantom measurements (0.86%). For pCT-based predictions, the agreement
deteriorated (average percentage of rejected pixels 2.98%), due to an enhanced impact of anatomy variations.
For predictions based on CBCT, combination of the first 2 fractions yielded gamma results in close agreement with
pre-treatment analyses (average percentage of rejected pixels 0.63% versus 0.35%, percentage of rejected beams
0.6% versus 0%). For the pCT-based approach, only combination of the first 5 fractions resulted in acceptable
agreement with pre-treatment results.
Conclusion: In-room acquired CBCT scans can be used for high accuracy IMRT fluence verification based on in-vivo
measured EPID images. Combination of γ results for the first 2 fractions can largely compensate for small accuracy
reductions, with respect to pre-treatment verification, related to intra-fraction motion and anatomy changes.
Keywords: EPID dosimetry, Treatment verification, Prostate cancer, CBCT* Correspondence: a.m.ali@erasmusmc.nl
Department of Radiation Oncology, Erasmus MC-Daniel den Hoed Cancer
Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
© 2013 Ali et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Ali et al. Radiation Oncology 2013, 8:211 Page 2 of 8
http://www.ro-journal.com/content/8/1/211Introduction
With the introduction of advanced treatment techniques
like intensity modulated radiotherapy (IMRT) and volumet-
ric modulated arc therapy (VMAT), the high-dose volume
can generally be better conformed to the target volume,
while achieving steep dose gradients towards surrounding
normal tissues. As a result, the accuracy of patient po-
sitioning and dose delivery becomes more critical. To ve-
rify delivered treatment fields, dosimetric pre-treatment
verification is performed prior to the first treatment
fraction using films, 2D detector arrays or Electronic
Portal Imaging Devices (EPIDs) in many institutes.
EPIDs have shown to be suitable for dose verification,
both pre-treatment and in-vivo because of their high
resolution, acquisition of digital data in 2D in a short ac-
quisition time, and high measurement accuracy [1-10].
In our institute, for over eight years, pre-treatment EPID
dosimetry is performed for all IMRT patients to com-
pare fluence maps delivered by the linac with TPS pre-
scriptions. For this purpose, prior to the first treatment
fraction, a full treatment including gantry rotations is
executed in the absence of the patient and treatment
couch, while acquiring for each beam an EPID image.
These images are converted into Portal Dose Images
(PDIs) [10] and compared with predictions, based on
the prescribed leaf sequence and monitor units (MU).
For several patients, major errors were captured prior
to the start of treatment [2]. Similar errors, like a
malfunctioning leaf or unintended changes of treat-
ment parameters in the record and verify system have
also occurred during patient treatment, after the pre-
treatment verification was successfully performed. So, in
spite of the high overall reproducibility of delivered IMRT
fluence maps (within 1% (1 SD), as assessed from repeated
EPID measurements) [11], pre-treatment verification does
not guarantee correct fluence delivery to the patient
during the course of treatment. For this purpose, in-
vivo dosimetry may be performed. When in-vivo PDI
predictions are based on the pCT of the patient, compari-
son with measured PDIs may result in an unreliable esti-
mate of the fluence delivered by the treatment unit,
because of changes in patient positioning and/or patient
anatomy (e.g., due to deformation, changing air gaps or
weight loss). To be able to accurately derive delivered
fluences irrespective of changes in patient anatomy, the
Split IMRT Field Technique (SIFT) [12] was introduced
in our institute. For this technique, each IMRT field is split
into a low MU static field and a residual IMRT field. From
the ratio of the PDIs of these fields, both being acquired
in a short time interval, the fluence of the IMRT field can
be derived within about 1% accuracy. The SIFT method
has several limitations: (i) deviations in beam output (cGy/
MU) and in open beam profile cannot be detected, because
they cancel out in the ratio image, (ii) in commerciallyavailable treatment planning systems (TPS), splitting of an
IMRT field into a static and residual modulated field is
often not possible, and (iii) the technique is only applicable
to IMRT; 3D conformal radiotherapy treatments or rota-
tional treatments, like Rapid Arc or VMAT, cannot be veri-
fied in a similar way.
CBCTs are increasingly being used to verify and cor-
rect target set-up. In this study, we investigated the
accuracy of in-vivo fluence verification by analyses based
on PDIs derived from measured EPID images and pre-
dictions calculated using a CBCT acquired in the same
treatment fraction. It was hypothesized that an in-room
acquired CBCT would better represent the patient’s
anatomy during acquisition of the EPID images than the
pCT would do, allowing for an increased PDI prediction
accuracy and resulting in an enhanced sensitivity for
detecting fluence maps deviations. Therefore, for
evaluation purposes, PDIs were also predicted using
the patients’ pCTs. It was investigated whether combining
in-vivo measurements performed in the first 1–5 fractions
could enhance agreement between measurements and
predictions, comparable to pre-treatment verification.
Materials and methods
Prostate IMRT, CBCT and pCT acquisition
Prostate IMRT plans, consisting of 5–7 fields, were gene-
rated with the Monaco TPS (Elekta AB) and delivered with
a step-and-shoot technique on an Elekta Precise treatment
unit. The beam energy was 10 MV. During the first three
treatment fractions, and once in the third and sixth week of
treatment, kilovoltage cone-beam projection images were
acquired using a gantry-mounted XVI system (Elekta AB),
CBCT images were reconstructed with a 2 mm slice dis-
tance using the XVI software. Treatment planning CT-
scans (pCT) with a 3 mm slice thickness and a 2.5 mm slice
distance were acquired with a Somaton Sensation Open
multi-slice CT scanner (Siemens, Erlangen, Germany).
In-vivo PDI measurement and prediction
Electronic portal images were acquired with a CCD-camera
based EPID (Cablon Medical Theraview Technology,
Leusden, The Netherlands). The dosimetric characteristics
of this EPID have been extensively reported before [13].
A measured EPID image was converted into an absolute
PDI by deconvolution with position-dependent cross-talk
kernels [10,14] and normalization with a conversion factor
derived from an EPID image for a symmetric 10 × 10 cm2
field irradiated with 100 MU.
To predict the in-vivo PDI, first a pre-treatment PDI
was calculated from the prescribed incident fluence on the
EPID (without patient in the beam), as derived from the
planned MLC leaf sequence and the number of MU [10].
Then corrections for beam attenuation and radiation
scattered in the patient (or phantom) towards the EPID
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neous phantom (EHP) [15]. For each treatment beam, a
separate EHP was calculated. These EHPs are derived
from the patients’ pCT (or CBCT) and for each ray line
have a polystyrene-equivalent thickness and equal distance
between the centre of mass and the EPID plane. Based on
a previously validated model for the treatment couch [16],
its beam absorption was also accounted for in the EHP.
Correction of CT values in CBCT images
Compared to conventional CT scanners, kilovoltage
CBCT images may suffer from an increased contribution
of scattered radiation, being largely dependent on the
patient geometry [17]. Consequently, CT values in those
CBCT images do generally not accurately represent elec-
tron densities, and the CBCT cannot directly be used for
establishing an EHP to be used for prediction of in-vivo
measured PDIs either. To adjust CT values, we applied a
previously described method [18]. First, the CBCT was
aligned to the pCT using rigid registration based on mu-
tual information. After resampling the pCT on the grid of
the CBCT, the Hounsfield units of the pCT were mapped
onto the CBCT. To preserve the shape of the body outline
in the CBCT scan, all pixels outside this surface were
assigned the standard CT value for air (−1000 HU) and all
pixels inside the body surface of the CBCT, but outside
the body outline of the pCT scan, were assigned the stan-
dard CT value for water (0 HU). Similarly, to preserve the
shape of air cavities in the CBCT scan, all pixels inside air
cavities in the CBCT got the value −1000 HU, and pixels
inside cavities in the pCT scan, but outside cavities in the
CBCT, were given the value 0 HU.
Validation of in-vivo fluence verification using
phantom measurements
To validate fluence verification based on comparison of
in-vivo measured PDIs with PDI predictions established
with an in-room acquired CBCT, IMRT treatment plans
of 10 prostate cancer patients were delivered to an ana-
tomical phantom, representing the caudal part of the ab-
domen and the upper part of the pelvic, made of solid
water and lung equivalent material (Gammex). For each of
the in total 68 fields, an EPID image was acquired during
beam delivery. For PDI prediction, EHPs were derived
from the CBCT after mapping the Hounsfield units of
the pCT (see above). For comparison, predictions were
also performed for the pCT, and pre-treatment analyses
(i.e., without phantom and treatment couch in the beam)
were performed as well.
Clinical evaluation of in-vivo fluence verification
Clinical evaluation was performed for a group of 50 con-
secutive radically treated prostate cancer patients. In each
fraction, prior to dose delivery, the position of the prostatewas verified by visualizing implanted gold markers using a
crossfire of kV and MV imaging [19]. An on-line set-up
correction was then applied for deviations exceeding 2 mm
in vector length. From the left and the right lateral beams,
a segment with 6 MU was split to be able to verify the
prostate position during treatment as well [20]. When a
4 mm threshold was exceeded, a correction for the intra-
fraction motion was applied. For verification purposes, in
the first three treatment fractions, and once in the third
and sixth week of treatment, also a CBCT was acquired
after delivery of all fields. For those fractions, acquired
PDIs were compared to PDIs, predicted both using the ac-
quired CBCTs with corrected Hounsfield units (see above)
and the pCT. In total 313 pre-treatment images and 1413
in-vivo dosimetry images were evaluated.
Comparison of measured and predicted PDIs
Measured and predicted PDIs were compared using γ eva-
luations, applying 3% global dose difference and 3 mm dis-
tance to agreement as reference criteria. Pixels with a
portal dose lower than 10% of the maximum dose inside
the field were ignored. For each comparison, the mean γ
and the percentage of rejected pixels, i.e., pixels with a γ
value larger than 1, were derived. In addition, a previously
published automatic decision scheme for comparison of
PDIs was applied [2]. According to this scheme, a PDI ana-
lysis is automatically approved when the percentage of fail-
ing pixels is less than 15% and the size of clustered areas
with pixels having a γ larger than 1 is smaller than 1 cm2.
For clustered areas with sizes between 1 cm2 and 5 cm2
this also applies when in each of them the mean gamma is
less than 1.5 and the maximum gamma is less than 2.
When larger differences are detected, the automatic evalu-
ation fails and a physicist needs to inspect the results visu-
ally to assess whether the observed deviations between
measured and predicted PDIs are clinically relevant or not.
Combining results from multiple fractions
To be able to distinguish systematic deviations between
measured and predicted PDIs from non-clinically relevant
deviations occurring in a single fraction, we applied a previ-
ously described method to combine γ results from the first
n treatment fractions [21]. Taking one field at a time, corre-
sponding γ pixel values from successive measurements
were first sorted in ascending order. Then, a composite
“low” γ-image [21] was derived with pixel values halfway
between the minimum and the median γ value per pixel.
Results
Validation of in-vivo fluence verification using
phantom measurements
When using the CBCT for in-vivo PDI prediction, the
average mean γ for the 68 evaluated beams was 0.30 ± 0.03
(1 SD) and the average percentage of rejected pixels was as
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t-test did not show any significant difference with respect
to the use of the pCT for predictions, yielding an average
mean γ of 0.31 ± 0.04% (p = 0.75) and an average percen-
tage of rejected pixels of 0.86 ± 0.66% (p = 0.93)). For
pre-treatment verification, deviations between measured
and predicted PDIs were slightly, but significantly, smaller
with an average mean γ of 0.26 ± 0.03 (p < 0.001) and
an average percentage of rejected pixels of 0.44 ± 0.44%
(p = <0.001). These improved results were mainly related
to a higher signal-to-noise ratio in the pre-treatment
images and uncertainties in the transmission model used
for in-vivo dosimetry.
Clinical evaluation of in-vivo fluence verification
Figure 1 shows PDI comparisons for a patient during
three treatment fractions, and the corresponding pre-
treatment analyses. For all beams in the first two fractions
and the last beams in the third fraction, the agreement be-
tween measured and predicted PDIs was clearly improved
when using the CBCT instead of the pCT for PDI predic-
tion. For the first beams in the third fraction, CBCT
performed worse than pCT. Apparently, the CBCT, ac-
quired at the end of treatment, did not accurately repre-
sent the patient anatomy at the start of treatment due to
intra-fraction anatomy changes, while for the pCT this ap-
plied for the end of treatment.
For the 1413 evaluated in-vivo measured images, the
distributions of observed mean γ values and percentages
of rejected pixels are depicted in Figure 2. In more than
70% of images the mean γ and/or percentage of rejected0 155
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Figure 1 γ evaluations of the observed differences between measure
one patient are shown. The beams are shown in the order that they were
reference, the results from the corresponding pre-treatment measurements
and the CBCT, acquired at the end of each fraction, are shown as well.pixels was lower for the CBCT-based PDI prediction
(Figures 2c and 2d). For images with lower γ parameters
for the pCT-based PDI prediction, the differences com-
pared to CBCT were generally small. By using CBCT
instead of pCT, the average mean γ reduced from
0.36 ± 0.10 to 0.32 ± 0.07 (p < 0.001). For pCT the percen-
tage of rejected pixels was already low (2.98 ± 4.88), but
with CBCT this reduced to 1.41 ± 2.78% (p < 0.001). The
corresponding values for the 313 pre-treatment images
were 0.28 ± 0.04 and 0.35 ± 0.41%, respectively. For pre-
treatment verification, all images passed the automated
PDI comparison scheme. For in-vivo measured images the
success rate reduced to 95.8% and 87.9% for CBCT- and
pCT-based PDI prediction, respectively.
Combining results from multiple fractions
Figure 3 shows that combining γ images from several
initial fractions could substantially reduce differences be-
tween in-vivo measurements and predictions based on
CBCT. Already when combining only the first 2 fractions,
the frequency distributions for the mean γ (Figure 3a)
and the percentage of rejected pixels (Figure 3b) ap-
proached the corresponding pre-treatment distribu-
tions very closely. Figure 4 clearly demonstrates that PDI
prediction based on CBCT resulted in smaller deviations
from measurements than pCT-based prediction did. After
combination of the first 2 fractions in the CBCT approach,
the difference in average percentage of rejected pixels
and mean gamma with pre-treatment became statistically
insignificant. In contrast, for pCT-based prediction, insig-
nificant differences in the mean gamma were obtained105 50 305 255 205
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Figure 2 Cumulative histograms of (a) observed mean γ values and (b) percentages of rejected pixels when comparing measured and
predicted PDIs. Prediction of in-vivo PDIs for the 1413 measured images was based on either CBCT or pCT. Results for the corresponding 313
pretreatment measurements were included as well. (c) and (d) show cumulative histograms of differences between CBCT- and
pCT-based prediction.
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gamma even 5 fractions should be combined (Figure 4a,
Figure 4b). In the pre-treatment approach, all fields passed
the automated PDI comparison scheme. After combi-
nation of 2 in-vivo fractions, the number of patients in
which one or more beams were rejected (rejected patients)
was two patients (2 images) for CBCT-based PDI predic-
tions; for pCT-based predictions this applied to nine pa-
tients (23 images). When combining 3 fractions these
numbers dropped to one patient (1 image) and eight pa-
tients (18 images), respectively. Two patients (2 images)Figure 3 Cumulative histograms of (a) observed mean γ values and (b
predicted PDIs for combined fractions. For in-vivo measured PDIs, result
combinations of the first 2, 3, 4, and 5 fractions. All in-vivo PDI predictions
the same fraction.were still rejected for predictions based on the pCT after
combining 5 fractions (Figure 4c).
Discussion
As far as we know, this is the first article describing the
use of kilovoltage CBCT for prediction of in-vivo mea-
sured PDIs to verify delivered IMRT fluence map with
an EPID. As expected, the agreement between measured
PDIs and CBCT-based predicted PDIs was slightly better
in phantom experiments than for patients. This is partly
attributed to intra-fraction patient motion. For some patient) percentages of rejected pixels when comparing measured and
s are shown for images acquired in the first fraction and for
were based on a CBCT. CBCT and in-vivo PDIs were always acquired in
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Figure 4 Comparison of predicted and measured PDIs.
(a) Averages of observed mean γ values, (b) averages of percentages
of rejected pixels, (c) number of patients in which one or more beams
were rejected according to the applied decision scheme. For in-vivo
analyses, predictions were based either on CBCT or pCT. Results are
shown for only the first fraction and for combinations of the first 2, 3,
4, and 5 fractions. The bars show the spread in the observations
(±1 SD). Values indicated by * are not statistically significant different
from the pre-treatment results, as established with paired t-tests.
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the patient’s anatomy for all treatment beams and hence
EPID acquisitions. Fraction 3 in Figure 1 shows an example.
At the start of treatment, the agreement between measured
and CBCT-based predicted PDIs was clearly less good
than for beams acquired near the end of the fraction,
i.e., shortly before the CBCT was acquired. Apparently,the acquired CBCT did not accurately represent the pa-
tient anatomy at the start of treatment, likely due to
intra-fraction anatomy changes. It should be noted that
the applied on-line set-up correction procedure to ac-
count for observed inter- and intra-fraction prostate
displacements, as derived from imaged implanted fidu-
cials, could not (fully) account for these effects.
Figure 3 shows that also for in-vivo dosimetric ana-
lyses based on CBCT in one single fraction, gamma de-
viations between measurements and predictions are low,
which allows detection of large, clinically relevant errors
immediately after the first fraction. Combination of in-
vivo results in multiple fractions reduces the impact of
intra-fraction motion, and averages out random varia-
tions in fluence delivery that do not occur in all frac-
tions. On the other hand, reproducible errors in fluence
delivery will not diminish. Consequently, by combining
multiple fractions, the sensitivity for detection of system-
atic errors in fluence delivery (i.e., occurring in all frac-
tions) will increase. This approach was initially suggested
by McDermott et al. [21]. For a group of 75 prostate can-
cer patients, they concluded that by combining in-vivo
dosimetry results from 3–5 treatment fractions using ‘low’
γ images, the results were in close agreement with pre-
treatment results. In this study, we also investigated the
use of these low γ images, both for CBCT- and pCT-
based predictions. For the pCT-based approach we found
that 4–5 fractions had to be combined to approach pre-
treatment results. When using CBCT, already combin-
ation of only the first 2 fractions yielded results in very
close agreement with pre-treatment analyses. Obviously,
even with some intra-fraction motion, CBCT scans do
much better represent patient anatomy during the frac-
tions than the pCT does and consequently a more accu-
rate fluence verification was possible than with pCT scans.
Over three years ago a computer-controlled system is
running in our department that daily checks whether
treatment parameters in our record-and-verify system
correspond to the parameters of the plan that was pre-
scribed and approved by the physician [22]. With this
system we also check pre-treatment whether a treatment
plan is correctly transferred from the planning system to
the record-and-verify system. In addition, a redundant
monitor unit calculation is performed prior to start of
treatment for all our patients. To correct for inter- and
intra-fraction motion in prostate cancer patients, on-
line set-up verification is performed before and during
each treatment fraction [19,20]. On top of these
individualized QA procedures, the IMRT performance
of our linacs is checked daily with EPID measurements
during the morning checks [23,24]. During the last eight
years, we performed pre-treatment verification for all
IMRT patients. For less than 0.3% of the patients, clini-
cally relevant errors were detected. Because of the large
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cation for all of them is a workload intensive practice,
involving measurements during evenings. Moreover, pre-
treatment verification inherently checks profiles that are
not necessarily equal to those delivered to the patient.
The results obtained in this work gave us confidence
that for prostate patients treated with a large number of
fractions, IMRT fluence delivery verification with pre-
treatment EPID dosimetry may be replaced by in-vivo
EPID dosimetry, when combined with the QA steps
mentioned before (in particular the pre-treatment check
on data transfer). This has the advantage that fluence de-
livery verification is performed while the patient is being
treated with a plan that has been checked pre-treatment
for data transfer errors. In practice, we verify the first 3
fractions, and also analyze the combined fractions, as de-
scribed in this paper. A relevant side effect is that mea-
surements in evenings and weekends can largely be
reduced. Of course, our method can also be used as a
supplement to pre-treatment verification, adding fluence
verification during patient treatment. In principal, this
can be done in each fraction.
Due to the high accuracy, in-vivo verification based on
CBCT allows for detection of clinically significant errors
with minimal user interaction after the first treatment
fraction, as is evident from the gamma results and high
percentage of accepted images (95.8%) according to our
automatic decision scheme. In case there are doubts on
the accuracy of the fluence delivery, a pre-treatment
measurement will be performed before the next fraction.
If this measurement confirms relevant errors in fluence
delivery, replanning should be performed before the next
treatment fraction is given. If, on the other hand, the
pre-treatment verification does not indicate any clinically
relevant deviations, in-vivo measurements will be re-
peated during the next fractions to verify whether the
PDI differences might be related to systematic deviations
in patient anatomy. Also in that case replanning should
be considered. For fractionated treatments with a large
number of fractions we consider this approach acceptable,
since corrections to compensate for delivery errors can
still be performed in the remaining treatment fractions.
McDermott et al. [21] suggested a similar approach.
Several groups have investigated the use of CBCT
scans to reconstruct delivered patient doses based on
measured EPID images (‘dose of the day’) [25,26]. In the
work of McDermott et al. [25] measured EPID images
were back-projected to multiple planes in a (kilovoltage)
CBCT, assuming a water-equivalent electron density.
Van Elmpt et al. [26,27] acquired megavoltage CBCT
scans with calibrated electron densities to derive the en-
trance energy fluence for each treatment beam by back-
projection of measured PDIs. These fluences were then
used for reconstruction of the dose distribution in theCBCT using a Monte Carlo dose algorithm. Our group
applied the SIFT method to derive the entrance fluence
from measured EPID images and then performed a dose
reconstruction using kilovoltage CBCT scans with corrected
Hounsfields units [28]. As replacement of the SIFT method,
we can now also apply the entrance fluences, as derived
from the CBCT-based in-vivo measurements, to reconstruct
the delivered patient dose.
The results of this study demonstrate for prostate can-
cer patients that high accuracy in-vivo verification of the
delivered 3D patient dose based on CBCT might be
complicated by intra-fraction anatomy variations. Likely,
this can be alleviated by the combining analyses performed
in 2D for many fractions. Investigations on the combi-
nation of several fractions in back projected EPID mea-
sured fluencies to estimate delivered 3D patients dose
distributions, is a topic for further research that is impor-
tant for so-called dose-guided radiotherapy.
In this paper we have demonstrated that in-room
CBCT and in-vivo measured EPID images can be used
for high accuracy in-vivo IMRT fluence verification for
prostate cancer patients that are known for intra-
fraction patient anatomy changes [20]. For other sites,
the impact of such effects on the accuracy of CBCT-
based fluence verification has to be investigated. The
developed technology may also be applied for fluence veri-
fication of VMAT, stereotactic treatment, and 3DCRT.
Accuracy assessment for these applications is a topic for
further study.Conclusion
In-room acquired CBCT scans can be used for high accu-
racy IMRT fluence verification for prostate cancer, based
on in-vivo measured EPID images. Combination of γ
results for the first 2 fractions can largely compensate for
small accuracy reductions with respect to pre-treatment
verification, related to intra-fraction motion and anatomy
changes. Compared to fluence verification based on the
pCT-scan, accuracy of verification using in-room CBCT
scans is clearly enhanced.Consent
In this study new tools to verify the accuracy of IMRT
delivery using an EPID were developed and evaluated.
This work did not affect patient’s treatment. Digital in-
formation, already routinely acquired for patient-specific
QA, was used, i.e., for patients no additional investiga-
tions or measurements were required. For these reasons,
according to the Ethics Committee of our hospital, no
ethical approval was required for this study. Providing
that all patient-related information was anonymized
prior to presentation and publication, informed consent
from the patients was not needed either.
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